BACKGROUND: Antiplatelet treatment remains the first choice for primary and secondary prevention of vascular diseases; even so, expected benefits may be offset by risk of bleeding, particularly cerebral hemorrhage. The aim of this study was to assess the influence of antiplatelet treatment on clinical outcome at hospital discharge. MATERIALS AND METHODS: Consecutive patients with first-ever stroke due to a primary intraparenchymal hemorrhage were prospectively identified over a 4-year period (2000-2003). Data on hemorrhage location, vascular risk factors, and antiplatelet and anticoagulant treatment were collected. At discharge, outcome was measured using the modified Rankin Scale (disabling stroke > or =3). Patients treated with anticoagulant therapy were excluded from the study. RESULTS: Of 457 consecutive patients with cerebral hemorrhage, 94 (20.5%) had been taking antiplatelet agents. The treated patients (mean age for antiplatelet group 78.9 +/- 9.0 years) were older than the nontreated patients (73.8 +/- 9.4, p = 0.02). In-hospital mortality was 23.4 and 23.1% (p = n.s.) for patients who had been taking antiplatelet agents or no treatment. Poor outcome at discharge was found in 52.1 and 59.7% (p = n.s.), respectively. Univariate analysis showed that age and coma at admission were predictors of disability at discharge, but antiplatelet treatment was not. Additionally, age and coma were shown to be determinants of disability at discharge after multivariate analysis: OR 1.03 per year (95% CI: 1.018-1.049), p < 0.001 and OR 1.68 (95% CI: 1.138-2.503), p = 0.009, respectively. CONCLUSIONS: Hemorrhagic stroke continues to be responsible for a high percentage of disability and death. Furthermore, it was seen here that functional outcome was independent of previous antiplatelet treatment.
BACKGROUND: Antiplatelet treatment remains the first choice for primary and secondary prevention of vascular diseases; even so, expected benefits may be offset by risk of bleeding, particularly cerebral hemorrhage. The aim of this study was to assess the influence of antiplatelet treatment on clinical outcome at hospital discharge. MATERIALS AND METHODS: Consecutive patients with first-ever stroke due to a primary intraparenchymal hemorrhage were prospectively identified over a 4-year period (2000-2003). Data on hemorrhage location, vascular risk factors, and antiplatelet and anticoagulant treatment were collected. At discharge, outcome was measured using the modified Rankin Scale (disabling stroke > or =3). Patients treated with anticoagulant therapy were excluded from the study. RESULTS: Of 457 consecutive patients with cerebral hemorrhage, 94 (20.5%) had been taking antiplatelet agents. The treated patients (mean age for antiplatelet group 78.9 +/- 9.0 years) were older than the nontreated patients (73.8 +/- 9.4, p = 0.02). In-hospital mortality was 23.4 and 23.1% (p = n.s.) for patients who had been taking antiplatelet agents or no treatment. Poor outcome at discharge was found in 52.1 and 59.7% (p = n.s.), respectively. Univariate analysis showed that age and coma at admission were predictors of disability at discharge, but antiplatelet treatment was not. Additionally, age and coma were shown to be determinants of disability at discharge after multivariate analysis: OR 1.03 per year (95% CI: 1.018-1.049), p < 0.001 and OR 1.68 (95% CI: 1.138-2.503), p = 0.009, respectively. CONCLUSIONS:Hemorrhagic stroke continues to be responsible for a high percentage of disability and death. Furthermore, it was seen here that functional outcome was independent of previous antiplatelet treatment.
Authors: Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss Journal: Neurocrit Care Date: 2016-02 Impact factor: 3.210
Authors: Verena van Ginneken; Patricia Engel; Jochen B Fiebach; Heinrich J Audebert; Christian H Nolte; Andrea Rocco Journal: Neurol Sci Date: 2018-02-14 Impact factor: 3.307
Authors: B B Thompson; Y Béjot; V Caso; J Castillo; H Christensen; M L Flaherty; C Foerch; K Ghandehari; M Giroud; S M Greenberg; H Hallevi; J C Hemphill; P Heuschmann; S Juvela; K Kimura; P K Myint; Y Nagakane; H Naritomi; S Passero; M R Rodríguez-Yáñez; J Roquer; J Rosand; N S Rost; P Saloheimo; V Salomaa; J Sivenius; T Sorimachi; M Togha; K Toyoda; W Turaj; K N Vemmos; C D A Wolfe; D Woo; E E Smith Journal: Neurology Date: 2010-09-08 Impact factor: 9.910
Authors: Martina B Goeldlin; Bernhard M Siepen; Madlaine Mueller; Bastian Volbers; Werner Z'Graggen; David Bervini; Andreas Raabe; Nikola Sprigg; Urs Fischer; David J Seiffge Journal: Eur Stroke J Date: 2021-11-16
Authors: Koen de Gans; Rob J de Haan; Charles B Majoie; Maria M Koopman; Anneke Brand; Marcel G Dijkgraaf; Marinus Vermeulen; Yvo B Roos Journal: BMC Neurol Date: 2010-03-18 Impact factor: 2.474
Authors: Claire J Creutzfeldt; Jonathan R Weinstein; W T Longstreth; Kyra J Becker; Thomas O McPharlin; David L Tirschwell Journal: J Stroke Cerebrovasc Dis Date: 2009 May-Jun Impact factor: 2.136
Authors: Claire J Creutzfeldt; Kyra J Becker; W T Longstreth; David L Tirschwell; Jonathan R Weinstein Journal: Stroke Date: 2009-09-24 Impact factor: 7.914
Authors: Airton Leonardo de Oliveira Manoel; Alberto Goffi; Fernando Godinho Zampieri; David Turkel-Parrella; Abhijit Duggal; Thomas R Marotta; R Loch Macdonald; Simon Abrahamson Journal: Crit Care Date: 2016-09-18 Impact factor: 9.097